In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust

Executive Summary

2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public. 

You may also be interested in...



Fancy Making A Drug? You May Want To Create A Diagnostic First.

Ochre Bio co-founder and CEO, Jack O’Meara, spoke to Medtech Insight about the company’s human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how a fledgling drug company's early work can mirror that seen in diagnostics.

Deals Shaping The Industry, February 2024

An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.

Execs On The Move: February 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV154571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel